Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$68.98 USD
-2.71 (-3.78%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Halozyme Therapeutics, Inc. has a market cap of $8.39B, which represents its share price of $71.69 multiplied by its outstanding shares number of 116.97M. As a mid-cap company, HALO's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
HALO 68.98 -2.71(-3.78%)
Will HALO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Other News for HALO
Is HALO signaling selling opportunity? Fell Below 50 Day Moving Average shows up after sinking 3.78%
HALO forms 50 Day Moving Average Support on October 2
Halozyme Announces Merger Agreement with Elektrofi
Stochastic Buy Signal appears for HALO after 2.18% move
HC Wainwright & Co. Raises Price Target for Halozyme Therapeutics (HALO) | HALO Stock News